Cell Therapy Bioprocessing

Cell Therapy Bioprocessing Market Demand, Investment And Forecast 2028    

According to our new research study on “Cell Therapy Bioprocessing Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by technology, cell type, end user,” the market is expected to reach US$ 30,052.61 million in 2028 from US$ 11,192.50 million in 2020. The market is estimated to grow with a CAGR of 13.5% from 2021-2028. Genome editing (also known as genome editing) refers to a collection of technologies that enable scientists to alter an organism’s DNA. These technologies allow for the addition, removal, or modification of genetic material at specific points in the genome. Several approaches to genome editing have been developed. CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats)is the most common, cheap and efficient system used for genome editing. It is a short for clustered regularly interspaced short palindromic repeats and CRISPR-associated protein. Since it is quicker, easier, more precise, and effective than other genome editing approaches, the CRISPR-Cas9 system has fueled a lot of interest in the scientific community.

In the prevention and treatment of human diseases, genome editing is of vital significance. The majority of genome editing research is currently conducted using cells and animal models to better understand diseases. It’s being researched for even a variety of diseases, including single-gene conditions such as cystic fibrosis, hemophilia, and sickle cell disease. Other genome editing technologies are Zinc-finger nuclease and TALENs stands for ‘Transcription activator-like effector nucleases’. Therefore, increasing research on the utilization of gene technology is driving the growth of the market.

Based on technology, the cell therapy bioprocessing market is segmented into bioreactor, lyophilization, electro spinning, controlflow centrifugation, ultrasonic lysis, genome editing technology, cell immortalization technology, and viral vector technology. The Bioreactor segment held the largest share of the market in 2020, whereas the genome editing technology segment is anticipated to register the highest CAGR of 14.5% in the market during the forecast period.

Get PDF Sample at @ https://www.theinsightpartners.com/sample/TIPRE00021550/

Cell therapies have shown positive results in treating various chronic diseases including rare genetic disorders by offering regenerative medicines and personalized medicines. Increasing need of treating chronic diseases have pushed the research and development activities resulting in growing cell therapy production and product approvals. Few instances are listed below for the cell therapies approvals that have contributed to the growth of the cell therapy bioprocessing market.

In May 2019, the Food and Drug Administration (FDA) approved Zolgensma, manufactured by AveXis, Inc. A subsidiary of Novartis AG. Zolgensa is designed to treat spinal muscular atrophy in children below two years and is given by infusing one-time into the vein.

In July 2020, Kite Pharma, Inc., a Subsidiary of Gilead Company, received FDA approval for its Tecartus. Tecartus is (CAR) T cell therapy designed to treat refractory mantle cell lymphoma (MCL) in adults. According to toe Gilead Company, Tecartus is the first approved (CAR) T cell therapy for mantle cell lymphoma, which is expected to be a new frontier in the treatment of mantle cell lymphoma.

In February 2021, Juno Therapeutics, Inc., a subsidiary of Bristol-Myers Squibb Company, received approval for its Breyanzi. Breyanzi is a cell-based gene therapy intended to treat certain types of large B-cell lymphoma in adults. The treatment is given after patient have not responded to minimum two other types of systemic treatment. However, Breyanzi in 2019, faced regulatory setback since its first filing; it is currently under the European Medicines Agency’s review and was validated in July 2020.

The cell therapy bioprocessing market majorly consists of the players such as Fresenius Kabi AG, Asahi Kasei Corporation, Sartorius AG, Merck KGaA, Thermo Fisher Scientific Inc, Corning Incorporated, Cytiva (GE Healthcare), Lonza, Repligen, and Catalent Inc;. The companies are adopting inorganic and organic growth strategies to expand their global footprints and product portfolio. For instance, in January 2020, Asahi Kasei expands scope of license regarding allogenic iPS cell-derived cartilage. The amended agreement grants Asahi Kasei a worldwide licence for iPS cell-related patents licenced by iPS Academia Japan in the area of treating osteoarthritis and meniscus injury in addition to traumatic articular cartilage damage, non-exclusive for iPS cell-inducing technology, and exclusive for chondrification technology.

Get Report Sample – https://www.theinsightpartners.com/reports/cell-therapy-bioprocessing-market

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi

E-mail: [email protected]

Phone: +1–646–491–9876